Analyst Trung Huynh from UBS asked about potential ACIP policy changes ... s focus on operational efficiency, capital allocation, and strategic R&D shifts positions Pfizer to navigate ...

risks related to the successful integration of the licensed asset with Pfizer’s business; disruption from the transaction making it more difficult to maintain business and operational ...

Global pharmaceutical company Pfizer (NYSE:PFE) missed Wall Street’s revenue expectations in Q1 CY2025, with sales falling ...

Despite a 6% revenue drop, Pfizer Inc (PFE) focuses on R&D advancements, cost savings, and dividend growth to drive future success.

And the key policy change impacts on Pfizer was a reduced ability to raise ... opportunities to drive improvements in productivity and operational efficiency in our R&D organization, again ...

FDA Commissioner Marty Makary was met with a skeptical set of Senate appropriators Thursday when he testified on his agency’s ...

The guidance does not include the potential impact of future tariffs and trade policy changes ... COVID revenues are declining, Pfizer’s non-COVID operational revenues improved in 2024, driven ...

We recently published a list of the 15 Best High-Yield Dividend Stocks for 2025 and Beyond. In this article, we are going to ...

Five-year follow-up data from the Phase 3 ARCHES trial shows XTANDI (enzalutamide) plus androgen deprivation therapy (ADT) reduces risk of death by 30% After a median follow-up of 61.4 months, ...